This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Patients with a diagnosis of thyroid cancer.
Patients with a pathological confirmation of differentiated thyroid cancer (DTC).
Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date).
Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy.
None
Adult RAI-R DTC patients from the rEHR database in China.
Cohort
Retrospective
Not listed
Proportion of Patients Receiving Second-line Systematic Therapy
Second-line systematic therapy includes lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Duration of Second-line Systematic Therapy
Duration of therapy with lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Proportion of Patients by Demographics and Clinical Characteristics
Demographics and clinical characteristics include sex/gender, Tumor Node Metastasis (TNM) stage, BRAF V600E and co-mutation status, presence of distant metastasis, and MKI tolerability-related comorbidities.
Age
Proportion of Patients Who had Surgery Prior to Second-line Systematic Therapy
Proportion of Patients Who Received 131I Radioiodine Therapy Prior to Second-line Systematic Therapy
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
